CanadaJAMP Temozolomide 140 mg capsules (DIN 02516829), lot RLTS0225A, distributed by JAMP Pharma Corporation in Canada are affected. The active ingredient temozolomide in the affected lot is out of specification. Verify if your product is the affected lot, consult your healthcare provider prior to discontinuing use or for health concerns, contact JAMP Pharma Corporation with questions, and report any side effects or other safety complaints to Health Canada.
What's being recalled
Depth of Recall: Retailers
Companies: JAMP Pharma Corporation, 1310 rue Nobel, Boucherville, QC J4B 5H3.
How to identify it
Brand: JAMP Pharma Corporation; Product Name: JAMP Temozolomide; Market Authorization: DIN 02516829; Dosage Form: Capsule; Strength: 140 mg; Lot Number: RLTS0225A
The hazard
The active ingredient (temozolomide) is out of specification in the affected lot.
What to do
Verify if your product is affected.
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Contact the recalling firm if you have any questions about the recall.
Report any health product related side effects to Health Canada.
Report any other health product safety complaints to Health Canada.
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)